Refine by
Prostate Biopsy Articles & Analysis
27 news found
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) ...
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
It combines the accuracy of MRI with the real-time monitoring of ultrasound to detect more clinically significant cancer, while preventing unnecessary biopsies. Unlike standard systematic biopsy, fusion can track lesions over time with imaging or repeat biopsy during active surveillance. ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends ...
In clinical partnership with Promaxo, we look forward to optimizing clinical workflow for office-based MRI guided biopsies in our high volume practice, and to collaborating on prostate cancer treatments, including brachytherapy and post placement confirmatory scans of hydrogel with Promaxo's MRI ...
Eric Klein, Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine, found that the use of IsoPSA led to significant provider behavior modification and a 55 percent net reduction in prostate biopsy recommendations. In the study, a diverse set of 38 providers from both ...
” The TransMedTech Institute has also made new detection applications of the Raman probe technology possible – in particular, for other types of cancer such as prostate cancer. Prostate cancer is the most common cancer directly affecting men in Canada. The Canadian Cancer Society says some 23,000 men will be diagnosed with prostate ...
When comparing the results of the miR Sentinel® Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of clinically significant cancer. This ...
NEW YORK and SAN JUAN, Puerto Rico, Sept. 1, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day". This urgent awareness team effort ...
The second place went to the Turin-based start-up NIB Biotech, that has developed the first rapid urine test for the screening of prostate cancer, capable of contemporary identifying the presence and aggressiveness of a possible case of cancer, helping doctors determine whether a prostate biopsy is necessary. "A rapid test for ...
Salman will discuss the planned commercial launch of miR Scientific's first product, the miR Sentinel™ Prostate Test. The award-winning, highly accurate liquid biopsy urine test was recently designated Breakthrough Designation status by the Food and Drug Administration, and is expected to be launched commercially later this year. ...
The Promaxo MRI is intended for urologists and interventional/urologic radiologists to perform surgical localization of prostatic lesions under Promaxo MRI guidance in an office or outpatient surgical setting. ...
Clinical evidence for micro-ultrasound is growing exponentially with publications from more than a dozen institutions reporting on more than 3,000 individual biopsy cases. Toronto, Canada -- (March 31, 2021) Exact Imaging™ (www.exactimaging.com), the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy ...
TORONTO, CANADA -- (March 23, 2021) Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announces $5.1M in financing provided by BDC Capital, through the Bridge Financing Program, and Export Development Canada (EDC). ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
Salman will introduce miR Scientific's proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recent FDA breakthrough designation and present miR's commercial launch plans for its non-invasive liquid biopsy urine test. Mr. Salman will also introduce the company's product pipeline and global growth initiatives, including a pioneering cooperation ...
The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically significant prostate cancer. The published analysis projected cost savings of the IsoPSA test based on previous clinical evidence of its effectiveness compared to a standard of care workup to guide the need for a repeat ...